Shear-thinning biocompatible embolization compositions, methods of making and use thereof

Abstract

The application provides a biocompatible embolization composition capable of shear thinning, and a preparation method and application thereof. The preparation method comprises the following steps: S1, first fluid preparation: uniformly mixing a biocompatible polymer, a first developing agent, a modifier and an initiator at room temperature to prepare a first fluid, wherein the molecular weight of the biocompatible polymer is 3000-6000; S2, second fluid preparation: uniformly mixing a crosslinking agent I, a crosslinking agent II, a catalyst, a thickening agent and a second developing agent at room temperature to prepare a second fluid; S3, third fluid preparation: mixing and reacting the first fluid and the second fluid to prepare a third fluid; and S4, embolization composition preparation: uniformly mixing the third fluid and a dry component at room temperature to prepare an embolization composition, wherein the particle size of the dry component is 7-800 nm. The preparation method cooperates the biocompatible polymer with the dry component in nanoscale to form a stable three-dimensional network structure, thereby endowing the composition with excellent shear thinning characteristics.

Description

Technical Field

[0001] This application relates to the field of biomedical materials technology, specifically to shear-thinning biocompatible embolic compositions, their preparation methods, and applications. Background Technology

[0002] Interventional embolization is a key minimally invasive technique for treating vascular diseases. Ideal embolic materials should possess characteristics such as easy delivery, precise placement, good biocompatibility, and high visibility. Currently, commonly used liquid embolic materials in clinical practice mainly include Onyx glue (ethylene-vinyl alcohol copolymer) and NBCA tissue glue. These materials play an important role in clinical applications, achieving the purpose of treating tumors, arteriovenous malformations, or achieving hemostasis by blocking blood flow in target vessels.

[0003] However, existing liquid embolization materials have significant performance drawbacks. Onyx glue has a high viscosity during injection, making it difficult to control and posing a risk of backflow; it also typically requires a specialized delivery system. NBCA glue has an extremely difficult-to-control polymerization time, demanding a high level of operator experience. Excessive polymerization can lead to catheter adhesion, while insufficient polymerization can result in ectopic embolization. Furthermore, the resulting polymer has high hardness, potentially damaging the vessel wall.

[0004] In recent years, hydrogel-based embolization systems have attracted widespread attention. However, traditional hydrogel precursor solutions have low viscosity and are easily diluted and washed away by blood flow, leading to incomplete embolization. Meanwhile, pre-formed high-viscosity gels are difficult to pass through thin microcatheters. Therefore, how to develop a novel embolization material that combines good delivery performance with stable embolization effect has become a technical challenge that urgently needs to be solved by those skilled in the art. Summary of the Invention

[0005] To address the problems of difficult and imprecise injection and poor viscosity control of existing embolic agents, this application provides a shear-thinning biocompatible embolic composition, its preparation method, and its application.

[0006] The first aspect of this application provides a method for preparing a shear-thinning biocompatible embolic composition, comprising the following steps: S1, preparation of a first fluid: mixing a biocompatible polymer, a first developer, a modifier, and an initiator uniformly at room temperature to prepare a first fluid, wherein the molecular weight of the biocompatible polymer is 3000-6000; S2, preparation of a second fluid: mixing a crosslinking agent one, a crosslinking agent two, a catalyst, a thickener, and a second developer uniformly at room temperature to prepare a second fluid; S3, preparation of a third fluid: mixing the first fluid and the second fluid to prepare a third fluid; S4, preparation of an embolic composition: mixing the third fluid with a dry component uniformly at room temperature to prepare an embolic composition, wherein the particle size of the dry component is 7-800 nm.

[0007] This preparation method utilizes the synergistic effect of biocompatible polymers and nanoscale dry components to form a stable three-dimensional network structure, thereby endowing the composition with excellent shear-thinning properties. Specifically, when delivered through a microcatheter, the high shear rate significantly reduces the viscosity of the composition, facilitating smooth injection and precise delivery. Once it reaches the target blood vessel region, the shear force disappears, the viscosity of the composition rapidly recovers, and it ultimately solidifies into an elastomer in a physiological solution, forming a stable embolus that effectively resists blood flow erosion. Furthermore, by controlling the molecular weight of the biocompatible polymer within the range of 3000-6000, it ensures that the composition possesses both suitable initial viscosity and the ability to form a solidified product with sufficient mechanical strength, avoiding the inability to form an elastic body due to excessively low molecular weight or the excessive injection pressure due to excessively high molecular weight.

[0008] Further, in step S1, the mass ratio of the biocompatible polymer, the first developer, the modifier, and the initiator is 100-200:30-60:10-30:1; in step S2, the mass ratio of crosslinking agent one, crosslinking agent two, the second developer, the thickener, and the catalyst is 500-1000:200-500:200-400:50-100:1. This ratio range optimizes the reactivity of each component and the physical properties of the final product, ensuring the uniformity of the developing effect and the integrity of the crosslinking network.

[0009] Furthermore, in step S1, the biocompatible polymer is selected from one or more of sodium alginate, chitosan, gelatin, poly(L-lactide), polydioxanone, poly(lactic-co-glycolic acid) acrylate, unsaturated polysiloxane, and polycaprolactone. These materials all have good biocompatibility and biodegradability, and can be gradually absorbed in the body, reducing long-term side effects.

[0010] Further, in step S1, the initiator is selected from one of azobisisobutyronitrile, di-tert-butyl peroxide, trifluoromethanesulfonic acid, and ammonium persulfate; the modifier is selected from one or more of methanol, ethylene glycol, glycerol, pentaerythritol, mannitol, silanol, and liquid polyethylene glycol. The initiator is used to initiate the polymerization reaction, and the modifier helps to adjust the hydrophilicity / hydrophobicity of the polymer and the reaction rate.

[0011] Further, in step S2, the first crosslinking agent is selected from one of polyethylene glycol diacrylamide, polyethylene glycol dimethacrylamide, polyethylene glycol diacrylate, and polyethylene glycol dimethacrylate; the second crosslinking agent is selected from one or more of dimethylchlorosilane, diethylchlorosilane, 3-vinyltrichlorosilane, hydrogen-terminated polydimethylsiloxane, and triphenylhydrazine. The introduction of the two-component crosslinking system makes the curing process more controllable, and the resulting elastomer has better toughness and stability.

[0012] Further, in step S2, the catalyst is selected from one of palladium catalyst, platinum catalyst, rhodium catalyst, ruthenium catalyst, and copper catalyst; the thickener is selected from one or more of butylated hydroxyanisole, dioctyl phthalate, triethyl citrate, and trimethylolpropane ethoxylate. The catalyst accelerates the crosslinking reaction, while the thickener helps to regulate the rheological properties of the system and prevent component sedimentation.

[0013] Furthermore, the first and second contrast agents are independently selected from one or more of iodolinolenic acid butyl ester, tantalum powder, iodized oil, and bismuth trioxide. The addition of the contrast agent enables the embolization composition to have good imaging effect under X-rays, facilitating real-time monitoring of the embolization location and extent by the physician during the procedure.

[0014] Further, in step S3, the volume ratio of the first fluid to the second fluid is 5:1 to 1:5, the reaction temperature is 25-85℃, and the reaction time is 2-12 hours; in step S4, the volume-to-mass ratio of the third fluid to the dry component is 40:1 to 10:1. Reasonable reaction conditions ensure the full progress of the prepolymerization reaction, while the specific volume-to-mass ratio ensures that the dry component can be uniformly dispersed and effectively construct a shear-thinning network.

[0015] Further, in step S4, the dry component is selected from one of dextran, cellulose acetate butyrate, hydrophilic fumed silica, and hydrophobic fumed silica. The nanoscale dry component is key to constructing shear-thinning properties; its interaction with the polymer matrix causes structural destruction and viscosity reduction under shear stress, followed by structural reconstruction and viscosity recovery upon resting.

[0016] A second aspect of this application provides a shear-thinning biocompatible embolic composition prepared by the above-described method. Because this method precisely controls the particle size, introduction timing, and reaction conditions of the nanoscale filler, the resulting product possesses a defined microstructure and excellent shear-thinning rheological properties. This structural stability ensures consistent performance across different batches, avoiding variations in embolic effects caused by process fluctuations. Therefore, in clinical applications, it can consistently achieve the effect of "low viscosity at injection, high viscosity after localization," ensuring the safety and effectiveness of treatment.

[0017] A third aspect of this application provides the application of the aforementioned biocompatible embolic composition in the preparation of vascular embolic materials. Based on the unique shear-thinning properties of this composition, it can significantly reduce the difficulty of interventional embolization procedures and decrease the risk of reflux or ectopic embolization due to improper viscosity control. Simultaneously, its excellent biocompatibility ensures the safety of long-term in vivo placement, broadening the application scope of this biocompatible material in the treatment of vascular embolization for arteriovenous malformations, aneurysms, and hypervascular tumors.

[0018] The present invention has the following beneficial effects: This invention constructs a three-dimensional network structure with shear-thinning properties by introducing nanoscale dry components of specific particle size and synergistic effects with biocompatible polymers, thus solving the problems of difficult injection and inaccurate positioning of existing embolic agents.

[0019] The embolization composition of the present invention has low viscosity when passing through a microcatheter, making it easy to deliver; after reaching the target blood vessel, the viscosity rapidly recovers and solidifies, effectively resisting blood flow erosion, avoiding ectopic embolism, and improving the safety and effectiveness of treatment.

[0020] The materials used in this invention have good biocompatibility and biodegradability. They can be naturally absorbed by the human body after treatment, eliminating the need for a second surgery to remove them, thus reducing the patient's pain and financial burden.

[0021] The preparation method of the present invention is simple, mild, easy to scale up, and the prepared composition has good imaging effect, which is convenient for clinical operation and monitoring. Attached Figure Description

[0022] Figure 1 This is a schematic diagram illustrating the precipitation process of an embolic composition injected into physiological saline according to one embodiment.

[0023] Figure 2 This is a schematic diagram of the digital subtraction angiography effect of an embolization composition according to an embodiment (before embolization).

[0024] Figure 3 A schematic diagram of the digital subtraction angiography effect of an embolization composition according to an embodiment (after embolization). Detailed Implementation

[0025] In some preferred embodiments, the biocompatible polymer may be selected from one or more of sodium alginate, chitosan, gelatin, poly(L-lactide), polydioxanone, poly(lactic-co-glycolic acid) acrylate, unsaturated polysiloxane, and polycaprolactone; its molecular weight may be selected from any value of 3000, 4000, 4500, 5000, 5500, and 6000 or any range between two of them.

[0026] In some preferred embodiments, the dry component may be selected from dextran, cellulose acetate butyrate, hydrophilic fumed silica, and hydrophobic fumed silica; its particle size may be selected from any value of 7nm, 20nm, 40nm, 100nm, 200nm, 500nm, and 800nm ​​or any range between two of these.

[0027] In some preferred embodiments, in step S3, the volume ratio of the first fluid to the second fluid can be selected from any value among 5:1, 3:1, 2:1, 1:1, 1:2, 1:3, and 1:5; the reaction temperature can be selected from any value among 25°C, 35°C, 45°C, 50°C, 65°C, 75°C, and 85°C; and the reaction time can be selected from any value among 2h, 4h, 6h, 8h, 10h, and 12h.

[0028] Example 1: This example provides a shear-thinning biocompatible embolic composition and its preparation method.

[0029] Preparation of raw materials First fluid raw materials: vinyl-terminated polydimethylsiloxane (molecular weight 5000, 2.5g), bismuth trioxide (first developer, 0.6g), liquid polyethylene glycol (modifier, 0.2g), azobisisobutyronitrile (initiator, 0.02g).

[0030] Second fluid raw materials: polyethylene glycol diacrylamide (crosslinking agent one, 1.2g), triphenyl hydrazine (crosslinking agent two, 0.8g), iodolinolenic acid butyl ester (second developer, 0.6g), triethyl citrate (thickener, 0.1g), and diphenylphosphine ferrocene palladium dichloride (catalyst, 0.002g).

[0031] Dry components: hydrophobic fumed silica (particle size 7-40nm).

[0032] Preparation method Preparation of the first fluid: Vinyl-terminated polydimethylsiloxane, bismuth trioxide, liquid polyethylene glycol, and azobisisobutyronitrile were mixed evenly at room temperature to prepare the first fluid.

[0033] Preparation of the second fluid: Polyethylene glycol diacrylamide, triphenyl hydrazine, butyl iodolinolenate, triethyl citrate, and diphenylphosphine ferrocene palladium dichloride were mixed evenly at room temperature to prepare the second fluid.

[0034] Preparation of the third fluid: The first fluid and the second fluid were mixed at a volume ratio of 1:1 and reacted at 65°C for 2 hours to prepare the third fluid.

[0035] Preparation of embolic composition: The third fluid and hydrophobic fumed silica were mixed evenly at a volume-to-mass ratio of 40:1 (ml / g) at room temperature to prepare the embolic composition.

[0036] Example 2: This example provides a shear-thinning biocompatible embolic composition and its preparation method.

[0037] Preparation of raw materials First fluid raw materials: vinyl-terminated polydimethylsiloxane (molecular weight 5000, 3g), iodolinolenic acid butyl ester (first developer, 0.6g), liquid polyethylene glycol (modifier, 0.2g), azobisisobutyronitrile (initiator, 0.02g).

[0038] Second fluid raw materials: polyethylene glycol diacrylate (crosslinking agent one, 1.6g), triphenylhydrazine (crosslinking agent two, 0.8g), iodolinolenic acid butyl ester (second developer, 0.6g), trimethylolpropane ethoxylate (thickener, 0.1g), platinum(0)-1,3-diethylene-1,1,3,3-tetramethyldisiloxane (catalyst, 0.002g).

[0039] Dry components: hydrophobic fumed silica (particle size 7-40nm).

[0040] Preparation method Preparation of the first fluid: Vinyl-terminated polydimethylsiloxane, iodolinolenic acid butyl ester, liquid polyethylene glycol, and azobisisobutyronitrile are mixed evenly at room temperature to prepare the first fluid.

[0041] Preparation of the second fluid: Polyethylene glycol diacrylate, triphenylhydrazine, iodolinolenic acid butyl ester, trimethylolpropane ethoxylate, and platinum(O)-1,3-diethylene-1,1,3,3-tetramethyldisiloxane were mixed evenly at room temperature to prepare the second fluid.

[0042] Preparation of the third fluid: The first fluid and the second fluid were mixed at a volume ratio of 2:1 and reacted at 50°C for 3 hours to prepare the third fluid.

[0043] Preparation of embolic composition: The third fluid and hydrophobic fumed silica were mixed evenly at a volume-to-mass ratio of 30:1 (ml / g) at room temperature to prepare the embolic composition.

[0044] Example 3: This example provides a shear-thinning biocompatible embolic composition and its preparation method.

[0045] Preparation of raw materials First fluid raw materials: poly(lactic-co-glycolic acid) acrylate (molecular weight 4500, 2.8g), bismuth trioxide (first developer, 0.8g), liquid polyethylene glycol (modifier, 0.2g), azobisisobutyronitrile (initiator, 0.02g).

[0046] Second fluid raw materials: polyethylene glycol diacrylate (crosslinking agent one, 1.6g), hydrogen-terminated polydimethylsiloxane (crosslinking agent two, 0.8g), bismuth trioxide (second developer, 0.8g), trimethylolpropane ethoxylate (thickener, 0.1g), platinum(O)-1,3-diethylene-1,1,3,3-tetramethyldisiloxane (catalyst, 0.002g).

[0047] Dry components: hydrophobic fumed silica (particle size 500nm).

[0048] Preparation method Preparation of the first fluid: Poly(lactic-co-glycolic acid) acrylate, bismuth trioxide, liquid polyethylene glycol, and azobisisobutyronitrile were mixed evenly at room temperature to prepare the first fluid.

[0049] Preparation of the second fluid: Polyethylene glycol diacrylate, hydrogen-terminated polydimethylsiloxane, bismuth trioxide, trimethylolpropane ethoxylate, and platinum(O)-1,3-diethylene-1,1,3,3-tetramethyldisiloxane were mixed evenly at room temperature to prepare the second fluid.

[0050] Preparation of the third fluid: The first fluid and the second fluid were mixed at a volume ratio of 1:1 and reacted at 50°C for 4 hours to prepare the third fluid.

[0051] Preparation of embolic composition: The third fluid and hydrophobic fumed silica were mixed evenly at a volume-to-mass ratio of 30:1 (ml / g) at room temperature to prepare the embolic composition.

[0052] Example 4: This example provides a shear-thinning biocompatible embolic composition and its preparation method.

[0053] Preparation of raw materials First fluid raw materials: poly(lactic-co-glycolic acid) acrylate (molecular weight 6000, 3g), iodolinolenic acid butyl ester (first developer, 0.6g), liquid polyethylene glycol (modifier, 0.3g), azobisisobutyronitrile (initiator, 0.02g).

[0054] Second fluid raw materials: polyethylene glycol dimethacrylate (crosslinking agent one, 1.6g), hydrogen-terminated polydimethylsiloxane (crosslinking agent two, 0.8g), bismuth trioxide (second developer, 0.8g), trimethylolpropane ethoxylate (thickener, 0.2g), platinum(O)-1,3-diethylene-1,1,3,3-tetramethyldisiloxane (catalyst, 0.002g).

[0055] Dry components: hydrophobic fumed silica (particle size 500nm).

[0056] Preparation method Preparation of the first fluid: Poly(lactic-co-glycolic acid) acrylate, iodolinolenic acid butyl ester, liquid polyethylene glycol, and azobisisobutyronitrile are mixed evenly at room temperature to prepare the first fluid.

[0057] Preparation of the second fluid: Polyethylene glycol dimethacrylate, hydrogen-terminated polydimethylsiloxane, bismuth trioxide, trimethylolpropane ethoxylate, and platinum(O)-1,3-diethylene-1,1,3,3-tetramethyldisiloxane were mixed evenly at room temperature to prepare the second fluid.

[0058] Preparation of the third fluid: The first fluid and the second fluid were mixed at a volume ratio of 1:1 and reacted at 50°C for 4 hours to prepare the third fluid.

[0059] Preparation of embolic composition: The third fluid and hydrophobic fumed silica were mixed evenly at a volume-to-mass ratio of 30:1 (ml / g) at room temperature to prepare the embolic composition.

[0060] Example 5: This example provides a shear-thinning biocompatible embolic composition and its preparation method.

[0061] Preparation of raw materials First fluid raw materials: vinyl-terminated polydimethylsiloxane (molecular weight 6000, 2.6g), iodolinolenic acid butyl ester (first developer, 0.6g), liquid polyethylene glycol (modifier, 0.3g), azobisisobutyronitrile (initiator, 0.02g).

[0062] Second fluid raw materials: polyethylene glycol dimethacrylate (crosslinking agent one, 1.6g), hydrogen-terminated polydimethylsiloxane (crosslinking agent two, 0.8g), bismuth trioxide (second developer, 0.8g), triethyl citrate (thickener, 0.2g), platinum(O)-1,3-diethylene-1,1,3,3-tetramethyldisiloxane (catalyst, 0.002g).

[0063] Dry component: hydrophilic fumed silica (particle size 30nm).

[0064] Preparation method Preparation of the first fluid: Vinyl-terminated polydimethylsiloxane, iodolinolenic acid butyl ester, liquid polyethylene glycol, and azobisisobutyronitrile are mixed evenly at room temperature to prepare the first fluid.

[0065] Preparation of the second fluid: Polyethylene glycol dimethacrylate, hydrogen-terminated polydimethylsiloxane, bismuth trioxide, triethyl citrate, and platinum(O)-1,3-diethylene-1,1,3,3-tetramethyldisiloxane were mixed evenly at room temperature to prepare the second fluid.

[0066] Preparation of the third fluid: The first fluid and the second fluid were mixed at a volume ratio of 1:1 and reacted at 45°C for 2 hours to prepare the third fluid.

[0067] Preparation of embolic composition: The third fluid and hydrophilic fumed silica were mixed evenly at a volume-to-mass ratio of 30:1 (ml / g) at room temperature to prepare the embolic composition.

[0068] Comparative Example 1: This comparative example did not use a biocompatible polymer with an appropriate molecular weight.

[0069] In this comparative example, vinyl-terminated polydimethylsiloxane with a molecular weight of 1000 was used instead of vinyl-terminated polydimethylsiloxane with a molecular weight of 5000 in Example 1. Other components, contents and preparation methods were the same as in Example 1.

[0070] Comparative Example 2: This comparative example did not use a biocompatible polymer with an appropriate molecular weight.

[0071] In this comparative example, vinyl-terminated polydimethylsiloxane with a molecular weight of 10,000 was used instead of vinyl-terminated polydimethylsiloxane with a molecular weight of 5,000 in Example 1. Other components, contents and preparation methods were the same as in Example 1.

[0072] Application Example 1: Hydrophobicity Test of Embolizing Composition The embolic composition prepared in Example 1 was injected into physiological saline using a syringe, and the precipitation was as follows. Figure 1 .

[0073] Application Example 2: Intravascular Imaging Test The prepared embolic composition was injected into the blood vessel, and digital subtraction angiography (DSA) was used to observe its imaging and embolization status. Figure 2 and Figure 3 It can be clearly seen that the embolization composition of the present invention has excellent imaging effect.

[0074] This application presents tests on the rheological and curing properties of the embolization compositions prepared in the examples and comparative examples.

[0075] Viscosity test: The steady-state shear viscosity of the composition was determined at room temperature using a rotational rheometer.

[0076] Injection pressure test: Simulating a clinical interventional surgical environment, a standard 1mL syringe connected to a microcatheter of a specific inner diameter is used to determine the pressure required to eject the composition at a constant rate.

[0077] Shear thinning characteristics determination: The viscosity change at different shear rates is measured using a rheometer to observe whether the viscosity decreases significantly with increasing shear rate.

[0078] Elastomer formation test: The composition was injected into a 0.9% physiological sodium chloride solution at 37°C, and it was observed whether a phase transition occurred and an elastic solid gel was formed.

[0079] Table 1 Test results of the examples and comparative examples Examples 1-6 all exhibited excellent overall performance, with moderate viscosity (63-75 cp), low injection pressure, and significant shear-thinning characteristics, rapidly solidifying into an elastomer after injection into physiological saline. This indicates that when the molecular weight of the biocompatible polymer is controlled within the range of 3000-6000 and combined with nano-dry components of specific particle sizes (such as fumed silica), effective physical or chemical interactions can be formed between the polymer segments and nanoparticles, constructing a dynamic three-dimensional network structure. This structure provides sufficient viscosity to maintain its morphology under static or low shear conditions, while under high shear conditions (such as injection through a microcatheter), the network structure is disrupted, leading to a decrease in viscosity and thus achieving smooth delivery.

[0080] Comparative Example 1 used vinyl-terminated polydimethylsiloxane with a molecular weight of 1000. Test results showed that its viscosity was extremely low (23 cp), making it unable to form an elastomer and lacking shear-thinning properties. This is mainly because the polymer's molecular weight is too low and its chain length too short, making it difficult to form entanglements or effective cross-linking networks with the nano-dry components. This results in the system exhibiting liquid-like behavior, unable to remain in the blood vessel and solidify into an embolus.

[0081] Comparative Example 2 used vinyl-terminated polydimethylsiloxane with a molecular weight of 10,000. Although this sample could form an elastomer, its viscosity was as high as 672 cp, resulting in excessively high injection pressure and a lack of shear-thinning properties. This is because the excessively high molecular weight leads to excessively high bulk polymer viscosity, making molecular chain movement difficult. The nano-dry components cannot construct a reversible shear-thinning network within it, resulting in excessive resistance during injection, which does not meet the requirements of minimally invasive clinical procedures.

[0082] Comparing Examples 3 and 4, it can be seen that, under the same formulation system, as the molecular weight of the biocompatible polymer increases from 4500 to 6000, the viscosity of the composition slightly increases from 63 cp to 71 cp. This indicates that within the preferred range, increasing the molecular weight moderately increases the viscosity of the system, but both remain within a suitable range for low injection pressure, and both achieve shear thinning and elastomer curing, demonstrating the breadth and stability of this molecular weight window.

Claims

1. A method for preparing a shear-thinning biocompatible embolic composition, characterized in that, Includes the following steps: S1, Preparation of the first fluid: The first fluid is prepared by uniformly mixing the biocompatible polymer, the first developer, the modifier, and the initiator at room temperature, wherein the molecular weight of the biocompatible polymer is 3000-6000; S2, Preparation of the second fluid: The second fluid is prepared by uniformly mixing crosslinking agent one, crosslinking agent two, catalyst, thickener, and second developer at room temperature; S3, Preparation of the third fluid: The first fluid and the second fluid are mixed and reacted to prepare the third fluid; S4, Preparation of embolic composition: The third fluid and the dry component are mixed uniformly at room temperature to prepare an embolic composition, wherein the particle size of the dry component is 7-800 nm.

2. The preparation method according to claim 1, characterized in that, In step S1, the mass ratio of the biocompatible polymer, the first developer, the modifier, and the initiator is 100-200:30-60:10-30:1; in step S2, the mass ratio of the first crosslinking agent, the second crosslinking agent, the second developer, the thickener, and the catalyst is 500-1000:200-500:200-400:50-100:

1.

3. The preparation method according to claim 1, characterized in that, In step S1, the biocompatible polymer is selected from one or more of sodium alginate, chitosan, gelatin, poly(L-lactide), polydioxanone, poly(lactic-co-glycolic acid) acrylate, unsaturated polysiloxane, and polycaprolactone.

4. The preparation method according to claim 1, characterized in that, In step S1, the initiator is selected from one of azobisisobutyronitrile, di-tert-butyl peroxide, trifluoromethanesulfonic acid, and ammonium persulfate; the modifier is selected from one or more of methanol, ethylene glycol, glycerol, pentaerythritol, mannitol, silanol, and liquid polyethylene glycol.

5. The preparation method according to claim 1, characterized in that, In step S2, the first crosslinking agent is selected from one of polyethylene glycol diacrylamide, polyethylene glycol dimethylacrylamide, polyethylene glycol diacrylate, and polyethylene glycol dimethacrylate; the second crosslinking agent is selected from one or more of dimethylchlorosilane, diethylchlorosilane, 3-vinyltrichlorosilane, hydrogen-terminated polydimethylsiloxane, and triphenylhydrazine.

6. The preparation method according to claim 1, characterized in that, In step S2, the catalyst is selected from palladium catalyst, platinum catalyst, rhodium catalyst, ruthenium catalyst, and copper catalyst; the thickener is selected from one or more of butylated hydroxyanisole, dioctyl phthalate, triethyl citrate, and trimethylolpropane ethoxylate.

7. The preparation method according to claim 1, characterized in that, The first developer and the second developer are independently selected from one or more of iodolinolenic acid butyl ester, tantalum powder, iodized oil, and bismuth trioxide.

8. The preparation method according to claim 1, characterized in that, In step S3, the volume ratio of the first fluid to the second fluid is 5:1 to 1:5, the reaction temperature is 25-85℃, and the reaction time is 2-12h; in step S4, the volume-to-mass ratio of the third fluid to the dry component is 40:1 to 10:

1.

9. A shear-thinning biocompatible embolic composition prepared by the preparation method according to any one of claims 1-8.

10. The use of the biocompatible embolic composition as described in claim 9 in the preparation of vascular embolic materials.

Images